Innate immune memory in cardiometabolic disease.

Autor:	Bahrar H; Radboud University Medical Center, Department of Internal Medicine and Radboud Institute for Molecular Life Sciences, 463, Geert Grooteplein Zuid 8, 6525 GA Nijmegen, The Netherlands., Bekkering S; Radboud University Medical Center, Department of Internal Medicine and Radboud Institute for Molecular Life Sciences, 463, Geert Grooteplein Zuid 8, 6525 GA Nijmegen, The Netherlands., Stienstra R; Radboud University Medical Center, Department of Internal Medicine and Radboud Institute for Molecular Life Sciences, 463, Geert Grooteplein Zuid 8, 6525 GA Nijmegen, The Netherlands.; Nutrition, Metabolism and Genomics Group, Division of Human Nutrition and Health, Wageningen University, Wageningen, The Netherlands., Netea MG; Radboud University Medical Center, Department of Internal Medicine and Radboud Institute for Molecular Life Sciences, 463, Geert Grooteplein Zuid 8, 6525 GA Nijmegen, The Netherlands.; Department of Immunology and Metabolism, Life and Medical Sciences Institute, University of Bonn, Bonn, Germany., Riksen NP; Radboud University Medical Center, Department of Internal Medicine and Radboud Institute for Molecular Life Sciences, 463, Geert Grooteplein Zuid 8, 6525 GA Nijmegen, The Netherlands.
Jazyk:	angličtina
Zdroj:	Cardiovascular research [Cardiovasc Res] 2024 Feb 17; Vol. 119 (18), pp. 2774-2786.
DOI:	10.1093/cvr/cvad030
Abstrakt:	Low-grade systemic inflammation is a key pathophysiological component of atherosclerotic cardiovascular disease (CVD), and long-term activation of myeloid cells is thought to be crucial for these effects. Obesity and associated metabolic complications including hyperglycaemia and dyslipoproteinaemia can induce long-lasting inflammatory reprogramming of the innate immune cells and their bone marrow progenitors, which in turn contributes to atherosclerosis. In this review, we discuss the mechanisms through which innate immune cells undergo long-term changes in their functional, epigenetic, and metabolic characteristics upon even short-term exposure to endogenous ligands, a process also termed 'trained immunity'. Inappropriate induction of trained immunity leads to the development of long-lasting hyperinflammatory and proatherogenic changes in monocytes and macrophages, an important factor in the development of atherosclerosis and CVDs. Knowledge of the specific immune cells and the distinct intracellular molecular pathways involved in the induction of trained immunity will reveal novel pharmacological targets that could be used to prevent or treat CVDs in the future. Competing Interests: Conflict of interest: M.G.N. is scientif founder of TTxD and Lemba Therapeutics. (© The Author(s) 2023. Published by Oxford University Press on behalf of the European Society of Cardiology.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu